Novartis International AG
Novartis Global Communications
CH-4002 Basel
Switzerland

http://www.novartis.com

MEDIA UPDATE • MEDIA UPDATE • MEDIA UPDATE

Novartis key multiple sclerosis product Gilenya® approved in China

- *Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older.*

- *Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China.*

- *Gilenya is the 3rd most prescribed MS disease modifying treatment worldwide. Today, Gilenya is widely recognized by doctors with over 283,000 patients treated with Gilenya to date*[1].

- *Novartis is committed to bringing innovation to China and to reimagining care for patients. Entresto® was approved in 2018. Following the approval of Cosentyx® in March, Gilenya is the next key Novartis product approved from the list of urgently needed drugs in China.*

Basel, July 19, 2019 — "It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent® demonstrate our commitment to Chinese patients. We are proud that Gilenya already demonstrated its benefits to over 283,000 MS patients worldwide. We are committed to bringing innovation to China with our key brands Entresto, Cosentyx and now Gilenya." said Marie-France Tschudin, President, Novartis Pharmaceuticals.

"I am delighted that we can now offer Gilenya to doctors and patients in China. There is a considerable need for MS treatments in China and we strive to bring clinical benefit to many patients with multiple sclerosis and improve their quality of life," said Ingrid Zhang, President, Novartis Pharmaceuticals China.

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or

approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at **www.novartis.com**.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartis or follow @NovartisNews for the latest News & Media Updates at https://twitter.com/novartisnews
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References
1. Novartis, data on file. July 2019.

# # #

Novartis Global External Communications
E-mail: media.relations@novartis.com

Antonio Ligi
Novartis Global External Communications
+41 61 324 1374 (direct)
antonio.ligi@novartis.com

Friedrich vonHeyl
Novartis Global Pharma Communications
+41 61 324 8631(direct)
+41 79 752 6955 (mobile)
friedrich.vonheyl@novartis.com

Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com